Seven tyrosine kinase inhibitor compounds with anti-angiogenic properties remain key drugs to treat advanced renal cell carcinoma. There is a strong rationale to develop therapeutic drug monitoring for these drugs. General considerations of such monitoring of the several groups of anticancer drugs are given, with a focus on oral therapy. Pharmacokinetics and the factors of inter- and intraindividual variabilities of these tyrosine kinase inhibitors are described together with an exhaustive presentation of their pharmacokinetic/pharmacodynamic relationships. The latter was observed in studies where every patient was treated with the same dose, and the results of several prospective studies based on dose individualization support the practice of increasing individual dosage in case of low observed plasma drug concentrations. Finally, the benefits and limits of therapeutic drug monitoring as a routine practice are discussed.
Fludarabine (Flu), administered as a prodrug Flu monophosphate, is a lymphodepleting agent used prior to hematopoietic stem cell transplantation (HSCT) which exhibits substantial pharmacokinetics (PK) variability, contributing to suboptimal outcomes. This study developed and validated a physiologically based pharmacokinetic (PBPK) model using literature‐based data and a middle‐out approach for Flu and its two main metabolites in adults and children, and evaluated its performance to predict individual Flu exposures in 28 pediatric HSCT patients using a virtual twin (VT) approach using PK‐Sim software. Different informed models with individual demographic and biological characteristics were assessed by comparing predicted and observed plasma exposures (AUC 0➔24h ) via fold error metrics and regression analyses. The PBPK model accurately reproduced observed Flu and metabolites concentrations in both adults and children. In the VT cohort, informing the model with plasma protein scaling factor and nuclear GFR improved drug exposure predictions in total (mean fold error (MFE) = 0.91) and unbound (MFE = 0.88) compartments with minimal bias in both Deming and Bland–Altman analyses. This model provided superior agreement between observed and predicted exposures, achieving improved agreement across statistical and regression approaches compared to the model with estimated GFR. PBPK‐based VT modeling enables accurate, individualized prediction of Flu PK in pediatric HSCT patients. These results support the implementation of model‐informed precision dosing to achieve personalized pediatric dosing of Flu in HSCT.